22 Febbraio 2019

FDA Grants Entrectinib Priority Review for NTRK+ Tumors and ROS1+ NSCLC

February 19, 2019 – The FDA has granted a priority review designation to a new drug application (NDA) for entrectinib as a treatment for select adult and pediatric patients with NTRK fusion–positive locally advanced or metastatic solid tumors, as well as patients with metastatic ROS1-positive non–small cell lung cancer (NSCLC), according to Genentech, the developer of the multikinase inhibitor. For NTRK fusion–positive tumors, entrectinib would be indicated for … (leggi tutto)